Cue Biopharma (CUE) vs Innate Pharma S.A. (IPHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma (CUE) has outperformed Innate Pharma S.A. (IPHA) over the past year, losing 0.2% versus a loss of 22.1%. Over five years, IPHA leads with a -74.1% price change compared with -94.0% for CUE. Innate Pharma S.A. is the larger company by market cap ($169.8 million vs $163.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | IPHA |
|---|---|---|
| Share price | $22.51 | $1.52 |
| Market cap | $163.52M | $169.78M |
| 1-day change | -2.72% | -4.40% |
| YTD return | +146.01% | -13.14% |
| 1-year return | -0.22% | -22.05% |
| 5-year return | -94.04% | -74.11% |
| EPS (TTM) | $-29.59 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $2.71 |
| 52-week low | $4.98 | $1.17 |
| Distance from 52-week high | -50.53% | -43.91% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +290.94% | +338.82% |
| Average volume | 269.82K | 158.98K |
| Shares outstanding | 7.26M | 111.70M |
| Employees | 29 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed IPHA by 21.8 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
CUE vs IPHA FAQ
Which is bigger, Cue Biopharma or Innate Pharma S.A.?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $169.78M compared with $163.52M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or IPHA?
CUE returned -0.22% over the past 12 months, compared with -22.05% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Innate Pharma S.A. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cue Biopharma and Biotechnology: Biological Products (No Diagnostic Substances) for Innate Pharma S.A..